Why the study?
Does apixaban reduce health care resource utilization and costs compared to warfarin in elderly patients with nonvalvular atrial fibrillation?
Does apixaban reduce health care resource utilization and costs compared to warfarin in elderly patients with nonvalvular atrial fibrillation?
Real-world data indicates that among elderly patients with nonvalvular atrial fibrillation, apixaban is associated with lower overall healthcare costs and resource utilization compared to warfarin, offsetting its higher pharmacy costs.
No takes yet. Share an insight, caveat, or question.
Supports the economic viability of apixaban over warfarin in elderly AF patients; extends clinical trial efficacy into.
Deitelzweig et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: